TIDMEKF
EKF Diagnostics Holdings PLC
22 December 2022
RNS Reach
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Point-of-Care update
Further innovation across established business
Launch of hand-held lactate analyser for the veterinary
market
following earlier launch of updated hand-held haemoglobin
analyzer with EKF Link digital connectivity
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global
diagnostics business , announces further product innovation in its
established Point-of-Care ("POC") business with the launch of
Lactate Scout Vet , a hand-held lactate analyzer designed
specifically for POC testing in veterinary settings. This follows
the launch of EKF's enhanced version of DiaSpect Tm , in October
2022, with wireless connectivity powered by the newly released EKF
Link middleware , which allows POC test results to be centralised
in one place and enables real-time remote management of data.
Lactate Scout Vet
Lactate Scout Vet uses the same proven technology that was
initially developed to provide elite sports coaches and athletes
with a precise and easy-to-use hand-held lactate test. Lactate
Scout Vet has the ability to deliver accurate lactate measurements
within 10 seconds, from just a 0.2 uL capillary blood sample, taken
via earlobe prick. It has quick and easy species selection options
and can store up to 500 results. Lactate Scout Vet is a
user-friendly device, and the simple to navigate e-paper display
provides excellent readability in varying light conditions, as well
as at different viewing angles.
Lactate testing is increasingly used in the veterinary clinic
for prognosis and diagnosis in a number of clinical presentations.
It can be applied as a rapid triage and risk stratification tool
assigning higher and lower risk categories. EKF's new Lactate Scout
Vet provides validated results comparable to laboratory-based
testing, allowing the veterinarian to obtain rapid, reliable
results at the POC and also helps to inform treatment decisions,
while providing the opportunity to monitor whole blood lactate
concentration in real-time.
DiaSpect Tm launched with secure POC connectivity
In October 2022, EKF launched a new version of DiaSpect Tm, now
powered by EKF Link, enabling new functions like Hematocrit
calculation, quality control management and patient data management
functions. DiaSpect Tm delivers laboratory quality results in one
second from the microcuvette being placed into the analyzer.
The haemoglobin analyzer is palm-sized, making it easily
transportable, and ideal for use in any screening setting even in
challenging climatic environments, and is now compatible with the
new state-of-the-art POC data management platform.
Mike Salter, CEO, of EKF, said: " With our vast experience in
lactate measurement in the clinical diagnostics market, we are
excited to launch our latest analyzer, Lactate Scout Vet, which is
designed specifically for the veterinary market. We are already a
well-established manufacturer, supplier, distributor and exporter
globally of lactate analyzers, delivering dependable pre and
post-sales support. We pride ourselves on developing easy-to-use
devices that provide reliable, fast and accurate results."
"Just a few weeks ago, our team successfully introduced our POC
testing connectivity solutions at MEDICA trade conference,
including the enhanced DiaSpect Tm hand-held haemoglobin analyser
and the new EKF Link digital connectivity software, both of which
were well received. It is great to see that we continue to make
further progress on new product and new market initiatives."
EKF's Lactate Scout Vet hand-held analyzer
DiaSpect Tm powered by EKF Link - a hand-held hemoglobin
analyzer
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Mike Salter, CEO Tel: +44 (0)29 2071 0570
Marc Davies, CFO
Singer Capital Markets (Nominated Adviser & Tel: +44 (0)20 7496 3000
Joint Broker)
Aubrey Powell / George Tzimas / Oliver
Platts
Investec Bank plc (Joint Broker) Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams / Ben
Farrow
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Applegarth Mob: +44 (0)7980 541 893 / +44 (0)7584
391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading global diagnostics business with custom
manufacturing facilities across sites in the US, UK and Europe for
a variety of life science products. EKF is focussed on the
following areas:
Point-of-Care Providing a portfolio of Point-of-Care analysers and
consumables, particularly for use in the area of Hematology
and Diabetes, for use in hospital and research laboratories,
doctor's offices, blood banks and anaemia screening
programmes. EKF has an estimated 80,000 hemoglobin,
hematocrit, HbA1c, glucose and lactate analysers in
regular use across more than 100 countries.
Central Laboratory Clinical chemistry, small lab analysers
Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor , Glycated
Albumin
Life Sciences Small and large-scale enzyme fermentation, custom
and contract manufactured products
Contract Manufacturing Bulk formulation, sample collection kits, private
labelling, molecular and forensic kits
Laboratory Testing Laboratory testing services certified under the Clinical
Laboratory Improvement Amendments ("CLIA") for high
complexity testing
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRATBBPTMTATBFT
(END) Dow Jones Newswires
December 22, 2022 02:00 ET (07:00 GMT)
International Brand Licensing (LSE:IBL)
Historical Stock Chart
From Nov 2024 to Dec 2024
International Brand Licensing (LSE:IBL)
Historical Stock Chart
From Dec 2023 to Dec 2024
